16:14 , Jul 20, 2018 |  BC Week In Review  |  Company News

Taiho exercises option for AB928

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) exercised an option to develop and commercialize AB928 from cancer company Arcus Biosciences Inc. (NYSE:RCUS) in Japan and other Asian territories, excluding China. Arcus will receive an option exercise payment...
17:49 , May 11, 2018 |  BC Week In Review  |  Clinical News

Arcus reports Phase I safety data for cancer candidate AB928

Arcus Biosciences Inc. (NYSE:RCUS) reported data from 85 healthy volunteers in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928 were well tolerated. Data were presented at the American...
02:46 , Mar 24, 2018 |  BioCentury  |  Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
18:00 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Arcus raises upsized $120M IPO

Arcus Biosciences Inc. (NYSE:RCUS) raised on March 14 $120 million through the sale of 8 million shares at $15 in an upsized IPO underwritten by Citigroup, Goldman Sachs and Leerink. The IPO price valued Arcus...
17:49 , Mar 15, 2018 |  BC Extra  |  Financial News

Modest first-day pop for Arcus after upsized $120M IPO

Arcus Biosciences Inc. (NYSE:RCUS) climbed $2.08 (14%) to $17.08 on Thursday after raising $120 million through the sale of 8 million shares at $15 in an upsized IPO underwritten by Citigroup, Goldman Sachs and Leerink....
20:28 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Immuno-oncology play Arcus raises $107M

On Nov. 13, immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital...
00:01 , Nov 14, 2017 |  BC Extra  |  Financial News

Immuno-oncology play Arcus raises $107M

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital and Leerink Partners...
19:52 , Sep 22, 2017 |  BC Week In Review  |  Company News

Taiho gets option to Arcus' candidates

Cancer company Arcus Biosciences (Hayward, Calif.) granted Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) an option to develop and commercialize compounds in Japan and other Asian territories excluding China. Arcus said the deal includes anything listed...
20:01 , Aug 18, 2017 |  BC Week In Review  |  Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
22:43 , Aug 17, 2017 |  BC Extra  |  Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...